235 related articles for article (PubMed ID: 24145035)
41. Biochemical characterization of the phosphatase domain of the tumor suppressor PH domain leucine-rich repeat protein phosphatase.
Sierecki E; Newton AC
Biochemistry; 2014 Jun; 53(24):3971-81. PubMed ID: 24892992
[TBL] [Abstract][Full Text] [Related]
42. The dystrophia myotonica WD repeat-containing protein DMWD and WDR20 differentially regulate USP12 deubiquitinase.
Olazabal-Herrero A; Bilbao-Arribas M; Carlevaris O; Sendino M; Varela-Martinez E; Jugo BM; Berra E; Rodriguez JA
FEBS J; 2021 Oct; 288(20):5943-5963. PubMed ID: 33844468
[TBL] [Abstract][Full Text] [Related]
43. The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation.
Nitsche C; Edderkaoui M; Moore RM; Eibl G; Kasahara N; Treger J; Grippo PJ; Mayerle J; Lerch MM; Gukovskaya AS
Gastroenterology; 2012 Feb; 142(2):377-87.e1-5. PubMed ID: 22044669
[TBL] [Abstract][Full Text] [Related]
44. Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese participants are associated with insulin resistance.
Andreozzi F; Procopio C; Greco A; Mannino GC; Miele C; Raciti GA; Iadicicco C; Beguinot F; Pontiroli AE; Hribal ML; Folli F; Sesti G
Diabetologia; 2011 Jul; 54(7):1879-87. PubMed ID: 21461637
[TBL] [Abstract][Full Text] [Related]
45. PHLPP Signaling in Immune Cells.
Lordén G; Lam AJ; Levings MK; Newton AC
Curr Top Microbiol Immunol; 2022; 436():117-143. PubMed ID: 36243842
[TBL] [Abstract][Full Text] [Related]
46. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms.
Brognard J; Sierecki E; Gao T; Newton AC
Mol Cell; 2007 Mar; 25(6):917-31. PubMed ID: 17386267
[TBL] [Abstract][Full Text] [Related]
47. PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth.
Liu J; Stevens PD; Li X; Schmidt MD; Gao T
Mol Cell Biol; 2011 Dec; 31(24):4917-27. PubMed ID: 21986499
[TBL] [Abstract][Full Text] [Related]
48. Xist reduction in breast cancer upregulates AKT phosphorylation via HDAC3-mediated repression of PHLPP1 expression.
Huang YS; Chang CC; Lee SS; Jou YS; Shih HM
Oncotarget; 2016 Jul; 7(28):43256-43266. PubMed ID: 27248326
[TBL] [Abstract][Full Text] [Related]
49. Exploitation of the ability of γ-tocopherol to facilitate membrane co-localization of Akt and PHLPP1 to develop PHLPP1-targeted Akt inhibitors.
Yan R; Chuang HC; Kapuriya N; Chou CC; Lai PT; Chang HW; Yang CN; Kulp SK; Chen CS
J Med Chem; 2015 Mar; 58(5):2290-8. PubMed ID: 25689347
[TBL] [Abstract][Full Text] [Related]
50. On the PHLPPside: Emerging roles of PHLPP phosphatases in the heart.
Lemoine KA; Fassas JM; Ohannesian SH; Purcell NH
Cell Signal; 2021 Oct; 86():110097. PubMed ID: 34320369
[TBL] [Abstract][Full Text] [Related]
51. microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2.
Liao WT; Li TT; Wang ZG; Wang SY; He MR; Ye YP; Qi L; Cui YM; Wu P; Jiao HL; Zhang C; Xie YJ; Wang JX; Ding YQ
Clin Cancer Res; 2013 Sep; 19(17):4662-72. PubMed ID: 23846336
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of PHLPP1 ameliorates cardiac dysfunction via activation of the PI3K/Akt/mTOR signalling pathway in diabetic cardiomyopathy.
Zhang M; Wang X; Liu M; Liu D; Pan J; Tian J; Jin T; Xu Y; An F
J Cell Mol Med; 2020 Apr; 24(8):4612-4623. PubMed ID: 32150791
[TBL] [Abstract][Full Text] [Related]
53. Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output.
Reyes G; Niederst M; Cohen-Katsenelson K; Stender JD; Kunkel MT; Chen M; Brognard J; Sierecki E; Gao T; Nowak DG; Trotman LC; Glass CK; Newton AC
Proc Natl Acad Sci U S A; 2014 Sep; 111(38):E3957-65. PubMed ID: 25201979
[TBL] [Abstract][Full Text] [Related]
54. Physiological activation of Akt by PHLPP1 deletion protects against pathological hypertrophy.
Moc C; Taylor AE; Chesini GP; Zambrano CM; Barlow MS; Zhang X; Gustafsson ÅB; Purcell NH
Cardiovasc Res; 2015 Feb; 105(2):160-70. PubMed ID: 25411382
[TBL] [Abstract][Full Text] [Related]
55. PHLiPPing the switch on Akt and protein kinase C signaling.
Brognard J; Newton AC
Trends Endocrinol Metab; 2008 Aug; 19(6):223-30. PubMed ID: 18511290
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of PHLPP1/2 phosphatases rescues pancreatic β-cells in diabetes.
Lupse B; Annamalai K; Ibrahim H; Kaur S; Geravandi S; Sarma B; Pal A; Awal S; Joshi A; Rafizadeh S; Madduri MK; Khazaei M; Liu H; Yuan T; He W; Gorrepati KDD; Azizi Z; Qi Q; Ye K; Oberholzer J; Maedler K; Ardestani A
Cell Rep; 2021 Aug; 36(5):109490. PubMed ID: 34348155
[TBL] [Abstract][Full Text] [Related]
57. PHLPP1 inhibits the growth and aerobic glycolysis activity of human ovarian granular cells through inactivating AKT pathway.
Yang X; A M; Gegen T; Daoerji B; Zheng Y; Wang A
BMC Womens Health; 2024 Jan; 24(1):25. PubMed ID: 38184561
[TBL] [Abstract][Full Text] [Related]
58. USP46 Inhibits Cell Proliferation in Lung Cancer through PHLPP1/AKT Pathway.
Wang W; Chen M; Xu H; Lv D; Zhou S; Yang H
Biomed Res Int; 2020; 2020():2509529. PubMed ID: 33029497
[TBL] [Abstract][Full Text] [Related]
59. PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.
Yu Y; Dai M; Lu A; Yu E; Merlino G
Oncogene; 2018 Apr; 37(17):2225-2236. PubMed ID: 29391600
[TBL] [Abstract][Full Text] [Related]
60. Aberrant expression of PHLPP1 and PHLPP2 correlates with poor prognosis in patients with hypopharyngeal squamous cell carcinoma.
Zhou J; Yu X; Wang J; Li T; Jin T; Lei D; Pan X
PLoS One; 2015; 10(3):e0119405. PubMed ID: 25793736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
